Discover the University of Edinburgh’s world-leading therapeutic expertise.
Explore how you can work with us as we open our doors to a campus that gives you full access to our academic researchers, patients, clinicians, scientists, partners and state of the art clinical and pre-clinical research facilities that can help you develop innovative ideas to deliver solutions to the world’s biggest medical challenges.
Edinburgh Innovations is the University of Edinburgh’s commercialisation service. We bring University of Edinburgh research to industry, working to identify ideas with value, and facilitating the process of bringing them to life in real-world applications.
We make ideas work for a better world.
Discover the University of Edinburgh’s world-class facilities that can support your projects from Bench to Bedside.
Access cutting edge facilities and technologies to make new discoveries and translational developments in human therapeutics. Our specialist support guides you through the journey to drug discovery, every step of the way.
High Throughput Microarray facility houses cutting-edge protein, antibody and transcriptome microarray facilities for the analysis of complex signalling pathways and secreted factors across pre-clinical and clinical samples types.
Phenotype screening facility is equipped with image-based screening platforms fully integrated with robotics and barcode tracking. Our team develops bespoke image analysis and informatics packages to quantify phenotypes. The facility has libraries of annotated reference molecules on assay-ready plates for drug discovery screens.
Pre-clinical imaging facility is part of a suite of state-of-the facilities dedicated to live-imaging of small animal models. It houses high-field magnetic resonance imaging (latest scanner 9.4 Tesla), ultrasound, micro PET/CT imaging and optical imaging. It can be used for in vivo non-invasive imaging of structure and function of all organs and tissues of the body.
Large Animal Research Imaging Facility (LARIF) is a unique facility in Europe with the capability for experimental surgery, monitoring and imaging of large animals (MRI, CT, Fluoroscopy and Ultrasound). It is a custom-built facility including ICU and Cat2 containment suites with technical and veterinary support 24-7, all year round.
Edinburgh Clinical Trials Unit (ECTU), underpinned by research governance, provides expert support to develop, design and deliver world-class clinical trials. The Unit provides trial management, medical statistics and data management. Strong links with NHS Lothian allows access to curated patient data sets for research purposes.
Explore the core facilities, shared equipment and expertise enabling our researchers to deliver cutting-edge research.
Expert facilites for Healthcare and Disease Management, Pharmaceuticals and Medical Biotechnology,
Life Sciences and Biotechnology, Food and Drink, Agri-Tech, Agri-Food and Plant Biology.
Discover the University of Edinburgh’s innovative creative data capability led by an exceptional team of experts.
Neil Carragher, a phenotypic screening pioneer with extensive industry experience, is Director of Edinburgh Cancer Discovery Unit, leads Edinburgh Phenotypic Assay Centre and is a co-founder of Pheno Therapeutics, developing remyelinating therapies for multiple sclerosis sufferers.
Luca Cassetta is an immunologist with extensive experience in human macrophage biology, clinical material handling, multicolour flow cytometry, and genome-wide studies that contributed to the development of the Macomics screening platform. Luca is a scientific co-founder of Macomics and currently Principal Investigator at the University of Edinburgh.
Shareen Forbes is a Honorary Consultant in Diabetes at the University of Edinburgh and NHS Lothian and has been Lead Physician for the Islet Transplant Programme in Scotland since 2010. Shareen is on the Novo Nordisk UK Scientific Council and her work is focussed on improving outcomes for those living with type 1 diabetes.
Jonathan Fallowfield excels in translational liver research. He has pioneered bench-to-bedside work on the antifibrotic and vasoactive effects of human-2 relaxin in chronic liver disease and is currently leading precision medicine projects in Non-Alcoholic Fatty Liver Disease (NAFLD) incorporating big data/AI, digital pathology and bioengineering.
Veronique Miron is an expert in neuroimmunology, MRC Senior Research Fellow, and Dementia Research Institute Group Leader, investigating the regenerative properties of inflammation to drive central nervous system white matter health across the lifespan. Her team is leading in discovering novel therapeutic targets for intervention in neurodegenerative disorders and neurological dysfunction by identifying the glial interactions involved.
Emily Sena specialises in the validity of preclinical research with a background in pharmacology and neuroscience. Her interests are in the use of meta-research approaches to drive improvements in the validity, transparency and reproducibility of primary research using laboratory models of human diseases. Her work has informed laboratory practice guidelines, editorial policy and clinical trials design. Emily is the convenor of CAMARADES – a research group set up to improve translation from preclinical research to the clinic and winner of the 2021 British Neuroscience Association Credibility Prize.